Literature DB >> 10796490

Lobeline for smoking cessation.

L F Stead1, J R Hughes.   

Abstract

BACKGROUND: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.
OBJECTIVES: The objective of this review was to assess the effects of lobeline on long term smoking cessation. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register. SELECTION CRITERIA: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up. MAIN
RESULTS: We identified no trials meeting the full inclusion criteria including long term follow-up. REVIEWER'S
CONCLUSIONS: There is no evidence available from long term trials that lobeline can aid smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796490     DOI: 10.1002/14651858.CD000124

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  8 in total

Review 1.  A review of smoking cessation interventions.

Authors:  Ashish Maseeh; Gagandeep Kwatra
Journal:  MedGenMed       Date:  2005-06-07

Review 2.  Cholinergic functioning in stimulant addiction: implications for medications development.

Authors:  Mehmet Sofuoglu; Marc Mooney
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

3.  [Guidelines for smoking cessation - update 2010].

Authors:  Alfred Lichtenschopf
Journal:  Wien Klin Wochenschr       Date:  2011-05-16       Impact factor: 1.704

Review 4.  Nicotine receptor partial agonists for smoking cessation.

Authors:  Kate Cahill; Nicola Lindson-Hawley; Kyla H Thomas; Thomas R Fanshawe; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2016-05-09

5.  Lobeline Effects on Cognitive Performance in Adult ADHD.

Authors:  Catherine A Martin; Paul A Nuzzo; John D Ranseen; Mark S Kleven; Greg Guenthner; Yolanda Williams; Sharon L Walsh; Linda P Dwoskin
Journal:  J Atten Disord       Date:  2013-08-21       Impact factor: 3.256

Review 6.  Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Authors:  August R Buchhalter; Reginald V Fant; Jack E Henningfield
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Antiepileptic activity of lobeline isolated from the leaf of Lobelia nicotianaefolia and its effect on brain GABA level in mice.

Authors:  Abrar M Tamboli; Rukhsana A Rub; Pinaki Ghosh; S L Bodhankar
Journal:  Asian Pac J Trop Biomed       Date:  2012-07

8.  An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.

Authors:  P Bader; P McDonald; P Selby
Journal:  Tob Control       Date:  2008-10-09       Impact factor: 7.552

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.